The Regenerative Medicine Market size was valued at USD 31.50 Bn. in 2021 and the total revenue is expected to grow by 9.8% from 2022 to 2029, reaching nearly USD 66.54 Bn. Regenerative Medicine is the branch of the medicines that develops methods to repair, regrow or replace damaged or diseased cells, tissues or organs. This medicine includes the generation and the use of the therapeutic stem cells, tissue engineering and the production of the artificial organs. Although it encompasses a wide range of applications, it is strongly related to repair or replace parts of tissues (i.e., bone, cartilage, blood vessels, bladder, skin). Frequently, the tissues involved need specific mechanical and structural characteristics to function properly. Regenerative Medicine have also been used to describe initiatives to accomplish particular biochemical operations employing cells with an artificial support system (for example, artificial pancreas or liver). Regenerative Medicines and Advanced Therapies financing has soared to new heights raising $14.1 Bn in the first half. The surge of the investment in the sector has made the H1, Regenerative medicine sector the strongest half on the record and has put this sector on a path, whch broke financing records despite the challenges in Covid-19 pandemic. Regenerative medicines emerged as an industry about two decades ago, a number of therapies have received Food and Drug Administration approval. A fundamental standard of regenerative medicine to date is the delivery of therapeutic cells that directly contribute to the formation and function of new tissues. Several FDA approved products of Regenerative Medicne has contributed towards the overall growth of the market. These Regenerative Medicine products provide benefits in terms of healing and regeneration. Introducing the new products to the market has made it difficult for monetary investments required to earn FDA approval in the Regenerative Medicine field. Increasing the acceptance of stem cells technologies, tissue engineering and technological development in Regenerative Medicines is expected to generate a revenue share of $1.5 billion by 2024. Several major trends of the Regenerative Medicines are Cellular Therapy, Gene Therapy, Bioartifical Organs, 3D Bioprinting, Nanotechnology, Robotic Surgery that are contributing towards overall growth of Regenerative Medicine Market.
Research Methodolgy Regenerative Medicine Market:Primary and secondary data methodology is been used for collecting information from vendors and then a distilled comprehensive overview of the competitive landscape has identified main trends, differentiating approaches and market targets. Vendors analysis were used to categorise the Regenerative Medicine Market, and the split was determined by conducting primary interviews with industry participants, subject-matter experts, High level executives of key market players, and industry consultants, among other experts. These interviews helped to gather and verify crucial qualitative and quantitative data as well as to evaluate future market prospects. The report offers the assessments of the Regenerative Medicine Market based on consulting work, research and briefings with the vendors and the operators. Secondary research has done to determine the scope and uses of the Regenerative Medicne Market across the globe, as well as in depth analysis and market impact of Regenerative Medicine Market is studied.To know about the Research Methodology :- Request Free Sample Report
Scope of the Report:The report provides a comprehensive analysis of the global Regenerative Medicine Market. The report estimates the Regenerative Medicine Market, in terms of USD value from 2021 to 2029. In order to identify potential investment pockets, this report gives an analytical representation of the Regenerative Medicine industry together with current key trends, drivers and future forecasts. The report includes a thorough analysis of the market share for Regenerative Medicine as well as data on important drivers, restraints, and opportunities. A quantitative analysis of the existing market is done from 2021 to 2029 to show the potential for market growth across the globe. In addition, Porter's five forces study demonstrates the market power of both buyers and providers. The research offers a thorough analysis of the worldwide Regenerative Medicine market based on the level of competition and how it will develop over the forecast period.
Regenerative Medicine Market Dynamics:A huge amount of resource engagement in the terms of skill, technology and money as a favourable atmosphere for the numerous research programs are driving the Regenerative Medicine industry market growth. The major advancement in the clinical advancement in the field of the Regenerative Medines are first pre-commercial in-vivo gene editing therapy, advancement of novel CAR-T treatments and the genetically engineered oncolytic viruses in growing fields of Immuno-oncology could cure complicated and polygenic disorders. The Regenerative Medicine market has cooled from its highs in Q1, performance in Q2 . The public offerings raised in the first half, has been star performers. In H1, 14 cells and gene therapy companies went in public and with six additional IPOs already in Q3, the total number of IPOs has risen to 20, suprassing the full year record number of 14 IPOs set in the year 2020. Additional companies are ready to set in Regenerative Medicne market. Moreover, Private placemnts and venture financing has been increasing continuously which has driven the Regenerative Medicne market. Finacings by Deal Type Contributing to Drive the Regenerative Medicine MarketAccording to Alliance for the Regenrative Medicine’s annual report for 2021, 60% of 2,400 current Regenerative Medicines trials addressed the common conditions, demonstrating the Regenerative Medicnes sectors growth. Several companies are on track for approvals of new Regenerative Medicines globally, decisions are expected on sveral Regenerative Medicne Products across geographies. Currently 1,320 industry sponsored Regenerative Medicne trials ongoing worldwide. That has an increase of 100 trials since the end of 2020-driven primarily by the addition of the new South Korean and Taiwanese trial registries, with Asia –Pacific region acting as major centre for growth of Regenerative Medicine Market, the addition of these registries will help in better geographical trends and creating growth opportunity of Regenerative Medicine Market. Novel and innovative stem cells therapies are being driven by the significant advancement and external fundings, which has enabled the technological advancements through industrialization required to transform promising research and development programs into the high-quality commercial products. The venture capital investment in 2021 totaled over USD 22.7 billion, a significant growth in spending over the previous few years. Owing to this Regenerative Medicine Market is expected to drive in the forecasted perios. Several Companies are focused on regulating AOC3 activity in order to expand the hematopoietic stem cells, that are used in the Regenerative Medicines and in hematological malignancies where the expansion rates in the transplanted cells are low, this initatves has the potential to benefit all indications where an expansion of the haemopoietic stem cells is needed, thus contributing towards the growth opportunity in Regenerative Medicine Market.
Regenerative Medicine Market Segment Analysis:By Type Insights, the Regenerative Medicine Market is segmented into cell-based immunotherapy, tissue engineering , stem cells therapy, gene therapy. The cell based immunotherqpay segment has accounted for the largest revenue share in 2021 due to continuous improvements and developments of cell-based immunotherapies for providing cancer types. Significant investments in stem cell research and the redrafting of regulatory rules for their use in clinical applications, the stem cell and progenitor cell-based treatments category is anticipated to see the fastest growing CAGR over the course of the forecasted years. While autologous therapies are known for having one of the fastest growing CAGRs, allogenic stem cell-based therapies are predicted to account for the biggest revenue share. The development of regenerative medicines is supported by key vendors with specialised technologies who offer management, manufacturing, characterization, engineering, and quality control services as well as other facilities for clinical trials and other research. Consequently, the services sector is anticipated to experience rapid growth in response to an increase in R&D and clinical trials of regenerative therapies. The Tissue engineering segmet has accounted for a moderate revenue share in the year 2021. Regenerative Medicne are evolving rapidly with the implications for bioprinting of the tissues and organs in three dimensions Artificial tissues and organ bioprinting applications of 3D bioprinting is expected to drive the area of the Regenerative Medicine Market.By Application Insights, the oncology market accounted for the largest revenue share of more than 32% in 2021 due to the highest use of Regenerative Medicine treatments. Effective cancer treatment alternatives have been introduced as a result of a high cancer prevalence. Numerous governmental agencies as well as private businesses have invested in cancer research and the creation of cutting-edge cell therapies. It is also projected that the market will develop as a result of global initiatives to lessen the burden of cancer. The musculoskeletal disorders segmet has accounted for a moderate revune share in the year 2021. Development of the innovative orthopaedic therapies like stem cell therapy has aided in pain relief and healing time by lowering the need for medications and invasive surgery. The Micro Phyiological Systems have emerged as the next generatin of models for testing the efficacy of the Regeneartive Medicines in the treatment of the musculoskeletal problems.By End-User Insights, the end-users of the Regenerative Medicine Market is segmented into commercial industries, hospitals and clinics and government and academic research institutes. The government and the research institutes segment is has accounted significant revenue share in the year 2021. Rising Investment in the TERM based research by government and stem cell research centers for finding innovative therapy options for treatment are the major factors that are driving the revenue growth of this segment. The commercial industries segment has accounted for the moderate revenue in the year 2021 The field of the Regenerative Medicne has shown a rapid growth with a projectd 515 gene therapy developrs. Bluebird Bio Zolgensma and Novartis were approved by the U.S. Food and Drug Adminstration and European Medcines in Europe in May 2019.
Regenerative Medicine Market Regional Insights:The Regenerative Medicine Market in North America has accounted for the largest revune share in the year 2021. The large number of clinical trials in this region and the availability of the modern technology as well as existence of the research centers has contributed towards the growth of Regenerative Medicne Market in this region. For Instance, the U.S. Department of Health and Human services launched a “2020: A New Vision” campaign, in which the Regenerative Medicine is recognized as a major Healthcare Technology. The EuropeAN Union’s Pharmaceutical Strategy and the related initiatives has represented a crucial infection point for a region that has been leading designation for the Regenerative medicine products has accounted for the second largest revenue share in 2021. From 2018 to 2021, 224 new industry sponsored Regenerative Medicnes trials started in Europe, while more than that amount started in the US and Asia-Pacific. The Asia-Pacific market accounted for the third largest revenue share in 2021 due to rising demand for the stem cell treatment products , advanced healthcare systems as well as the availability of the government and private funding for stem cell research. China and Japan accounts for overall two-third of the Asia-Pacific Regenerative Medicine Market and are expected to drive the market growth throughout the forecasted period.
Regenerative Medicine Market Scope: Inquire before buying
Regenerative Medicine Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 31.50 Bn. Forecast Period 2022 to 2029 CAGR: 9.8% Market Size in 2029: US $ 66.54 Bn. Segments Covered: by Type Insights • Cell-based Immunotherapy • Gene Therapy • Stem-cell Therapy • Tissue Engineering • Others by End-User Insights • Commercial Industries • Hospitals & Clinics • Government & Academic Institutes by Application Area • Dermatology • Musculoskeletal • Immunology & Inflammation • Oncology • Cardiovascular • Ophthalmology • Others
Regenerative Medicine Market, by Region• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) • Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina, Columbia and Rest of South America)
Regenerative Medicine Market Key Players are:• Integra Lifesciences Corp.(US) • Osiris Therapeutics, Inc.(US) • Amgen Inc.(US) • Cesca Therapeutics, Inc.(US) • U.S. Stem Cell, Inc.(US) • Bristol-Myers Squibb(US) • Eli Lilly and Company(US) • NuVasive, Inc.(US) • Organogenesis, Inc.(US) • MiMedx Group, Inc.(US) • Cook Biotech, Inc.(US) • Pfizer, Inc.(US) • Abbott(US) • Vericel Corp.(US) • Baxter International, Inc.(US) • Astellas Pharma, Inc.(Japan) • Bayer AG(Germany) • Merck KGaA(Germany) • Boehringer Ingelheim(Germany) • Novartis AG(Switzerland) • F. Hoffmann-La Roche Ltd.(Switzerland) • GlaxoSmithKline (GSK)(UK) • AstraZeneca plc (UK) • Takara Bio, Inc.(Japan) • Corline Biomedical AB(Sweden) FAQs: 1. Who are the key players of the Regenerative Medicine Market? Ans. AstraZeneca plc, F. Hoffmann-La Roche Ltd., Integra Lifesciences Corp., Astellas Pharma, Inc., Cook Biotech, Inc., Bayer AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp., Novartis AG, GlaxoSmithKline (GSK), Baxter International, Inc., Boehringer Ingelheim, Amgen Inc., Cesca Therapeutics, Inc., U.S. Stem Cell, Inc., Bristol-Myers Squibb, Eli Lilly and Company, NuVasive, Inc., Organogenesis, Inc., MiMedx Group, Inc., Takara Bio, Inc., Osiris Therapeutics, Inc., Corline Biomedical 2. What is the growth rate of Regenerative Medicine Market? Ans. The Regenerative Medicine Market is growing at a CAGR of 9.8% over forecast period. 3. What is the market size of the Regenerative Medicine Market by 2029? Ans. The market size of the Information Technology Market by 2029 is expected to reach at USD 66.54 Bn. 4. Which was the leading segment in the Regenerative Medicine Market in the terms of application? Ans.Oncology segment was the leading segment in the year 2021 due to technological innovations and advancements in cell therapy and gene therapy. 5. Which are the leading market share countries in the Regenerative Medicine Market? Ans. Several companies have their establishment worldwide, North America has the highest market share followed by Europe and Asia.
1. Global Regenerative Medicine Market: Research Methodology 2. Global Regenerative Medicine Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Regenerative Medicine Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Regenerative Medicine Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Regenerative Medicine Market Segmentation 4.1 Global Regenerative Medicine Market, by Product Insights (2021-2029) • Cell-based Immunotherapy • Gene Therapy • Stem-cell Therapy • Tissue Engineering • Others 4.2 Global Regenerative Medicine Market, by End-User (2021-2029) • Commercial Industries • Hospitals & Clinics • Government & Academic Institutes 4.3 Global Regenerative Medicine Market, by Application Area (2021-2029) • Dermatology • Musculoskeletal • Immunology & Inflammation • Oncology • Cardiovascular • Ophthalmology • Others 5. North America Regenerative Medicine Market(2021-2029) 5.1 North America Regenerative Medicine Market, by Product Insights (2021-2029) • Cell-based Immunotherapy • Gene Therapy • Stem-cell Therapy • Tissue Engineering • Others 5.2 North America Regenerative Medicine Market, by End-User (2021-2029) • Commercial Industries • Hospitals & Clinics • Government & Academic Institutes 5.3 North America Regenerative Medicine Market, by Application Area (2021-2029) • Dermatology • Musculoskeletal • Immunology & Inflammation • Oncology • Cardiovascular • Ophthalmology • Others 5.4 North America Regenerative Medicine Market, by Country (2021-2029) • United States • Canada • Mexico 6. Europe Regenerative Medicine Market (2021-2029) 6.1. Europe Regenerative Medicine Market, by Product Insights (2021-2029) 6.2. Europe Regenerative Medicine Market, by End-User (2021-2029) 6.3. Europe Regenerative Medicine Market, by Application Area (2021-2029) 6.4. Europe Regenerative Medicine Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Regenerative Medicine Market (2021-2029) 7.1. Asia Pacific Regenerative Medicine Market, by Product Insights (2021-2029) 7.2. Asia Pacific Regenerative Medicine Market, by End-User (2021-2029) 7.3. Asia Pacific Regenerative Medicine Market, by Application Area (2021-2029) 7.4. Asia Pacific Regenerative Medicine Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Regenerative Medicine Market (2021-2029) 8.1 Middle East and Africa Regenerative Medicine Market, by Product Insights (2021-2029) 8.2. Middle East and Africa Regenerative Medicine Market, by End-User (2021-2029) 8.3. Middle East and Africa Regenerative Medicine Market, by Application Area (2021-2029) 8.4. Middle East and Africa Regenerative Medicine Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Regenerative Medicine Market (2021-2029) 9.1. South America Regenerative Medicine Market, by Product Insights (2021-2029) 9.2. South America Regenerative Medicine Market, by End-User (2021-2029) 9.3. South America Regenerative Medicine Market, by Application Area (2021-2029) 9.4. South America Regenerative Medicine Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 AstraZeneca plc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 F. Hoffmann-La Roche Ltd. 10.3 Integra Lifesciences Corp. 10.4 Astellas Pharma, Inc. 10.5 Cook Biotech, Inc. 10.6 Bayer AG 10.7 Pfizer, Inc. 10.8 Merck KGaA 10.9 Abbott 10.10 Vericel Corp. 10.11 Novartis AG 10.12 GlaxoSmithKline (GSK) 10.13 Baxter International, Inc. 10.14 Boehringer Ingelheim 10.15 Amgen Inc. 10.16 Cesca Therapeutics, Inc. 10.17 U.S. Stem Cell, Inc. 10.18 Bristol-Myers Squibb 10.19 Eli Lilly and Company 10.20 NuVasive, Inc. 10.21 Organogenesis, Inc. 10.22 MiMedx Group, Inc. 10.23 Takara Bio, Inc. 10.24 Osiris Therapeutics, Inc. 10.25 Corline Biomedical AB